Sanuwave Health (NASDAQ:SNWV) Posts Quarterly Earnings Results, Misses Expectations By $0.17 EPS

Sanuwave Health (NASDAQ:SNWV) announced its quarterly earnings results on Tuesday. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.17), FiscalAI reports. The business had revenue of $8.58 million during the quarter, compared to the consensus estimate of $13.75 million. Sanuwave Health had a net margin of 32.38% and a return on equity of 1,728.10%.

Sanuwave Health Trading Up 1.6%

Shares of NASDAQ:SNWV traded up $0.03 during trading on Tuesday, reaching $1.88. 92,741 shares of the company were exchanged, compared to its average volume of 113,433. The business’s fifty day simple moving average is $4.73 and its 200-day simple moving average is $12.91. The company has a debt-to-equity ratio of 4.87, a current ratio of 1.28 and a quick ratio of 0.89. Sanuwave Health has a 12-month low of $1.75 and a 12-month high of $36.20. The firm has a market capitalization of $16.17 million, a PE ratio of 7.83 and a beta of 1.47.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Sanuwave Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, November 4th. One equities research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average price target of $47.00.

About Sanuwave Health

SANUWAVE Health, Inc. is a medical technology company focused on regenerative medicine and advanced wound-care solutions. The company develops and commercializes noninvasive devices that use extracorporeal shock wave technology to stimulate biological responses in damaged or difficult-to-heal tissue. Its principal product is the dermaPACE system, which is designed to deliver acoustic shock waves to wound areas, including chronic diabetic foot ulcers. SANUWAVE has also pursued additional applications for its platform in areas such as orthopedic and soft-tissue healing, although the availability and regulatory status of specific products may vary by geography.